Wyeth

Genetics Institute, Inc.

Kathleen N Tomkinson

Neil M Wolfman

Soo-Peang Khor

Lisa Anne Collins-Racie

Christopher John Corcoran

Bethany Annis Freeman

Katy Evangelia Georgiadis

Tara K Crawford

Edward R LaVallie

Geertruida Machteld Veldman

John R McCoy

Debra D Pittman

Jing Li

Xiang-Yang Tan

Lynette A Fouser

Edward Roland Lavallie

Monique Davies

John Mccoy

Soo Peang Khor

Lynette Fouser

Geertruida M Veldan

Modified and stabilized propeptides of Growth Differentiation Factor proteins, such as GDF-8 and Bone Morphogenetic Protein-11, are disclosed. Also disclosed are methods for making and using the modified propeptides to prevent or treat human or animal disorders in which an increase in muscle tissue would be therapeutically beneficial. Such disorders include muscle or neuromuscular disorders (such as amyotrophic lateral sclerosis, muscular dystrophy, muscle atrophy, congestive obstructive pulmonary disease, muscle wasting syndrome, sarcopenia, or cachexia), metabolic diseases or disorders (such as such as type 2 diabetes, noninsulin-dependent diabetes mellitus, hyperglycemia, or obesity), adipose tissue disorders (such as obesity), and bone degenerative diseases (such as osteoporosis).

Modified and stabilized GDF propeptides and uses thereof

Antibodies and antigen-binding fragments thereof that bind interleukin-22 (IL-22), in particular, human IL-22, and their uses in regulating IL-22-associated immune responses are disclosed. The antibodies disclosed herein are useful in diagnosing, preventing, or treating IL-22-associated immune disorders, e.g., autoimmune disorders (e.g., arthritis).

Monoclonal antibodies against interleukin-22

Truncated aggrecanase proteins and nucleotides sequences encoding them as well as processes for producing them are disclosed. Additionally, aggrecanases with amino acid mutations that lead to increased stability and expression levels in comparison with wild-type or native aggrecanases are also disclosed. Aggrecanases of the invention are especially useful for development of compositions for treatment of diseases such as osteoarthritis. Methods for developing inhibitors of the aggrecanase enzymes and antibodies to the enzymes for treatment of conditions characterized by the degradation of aggrecan are also disclosed.

Truncated aggrecanase molecules

Disclosed are methods, DNA sequences, vectors and cell lines useful for the rapid generation of stable mammalian cell lines expressing high levels of recombinant proteins.

Rapid generation of stable mammalian cell lines producing high levels of

Growing community of inventors

Cambridge, MA, United States of America

Kathleen N Tomkinson